8-K: Moleculin Biotech Receives European Approval to Begin Recruiting for Phase 3 AML Trial

Moleculin Biotech has received its first European regulatory approval to begin recruiting for its Phase 3 MIRACLE trial evaluating Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).

Summary

• Moleculin Biotech has received regulatory approval in Europe to begin recruiting for its Phase 3 MIRACLE trial.
• The trial will evaluate Annamycin in combination with Cytarabine (AnnAraC) for the treatment of R/R AML patients.
• The MIRACLE trial will be a global study with sites in the US, Europe, and the Middle East.
• The company expects preliminary unblinded data from the first 45 subjects in the second half of 2025.
• The amended protocol allows for unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at 45 subjects.
• The company expects to reach the second unblinding (at 75 to 90 subjects) in the first half of 2026.
• The trial utilizes an adaptive design, randomizing subjects to receive HiDAC combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin.
• Part B of the trial will randomize approximately 244 additional subjects to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA and EMA for the treatment of relapsed or refractory AML.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the regulatory approval and progress in the clinical trial, but tempered by the need for additional financing.

Positives

• The company has received its first European regulatory approval to begin recruiting for the Phase 3 MIRACLE trial.
• The MIRACLE trial is progressing with site initiation and enrollment efforts.
• The amended protocol allows for earlier unblinding of preliminary efficacy data.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA and EMA.

Risks

• The company will require significant additional financing to conduct its clinical trials.
• The milestones described assume the company's ability to secure such financing on a timely basis.
• The study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Future Outlook

The company anticipates achieving milestones related to the MIRACLE trial, including site approvals, first subject treatment, and data unblinding, contingent on securing necessary financing.

Management Comments

• Walter Klemp, Chairman and Chief Executive Officer of Moleculin, stated that achieving the first country's approval puts the company another step closer to getting the study underway.
• Walter Klemp mentioned his commitment to operational execution and face-to-face meetings with investigators.

Industry Context

This announcement positions Moleculin Biotech among companies developing treatments for AML, a challenging hematological malignancy. The focus on overcoming multidrug resistance and cardiotoxicity aligns with current trends in cancer drug development.

Comparison to Industry Standards

• The adaptive trial design is consistent with modern clinical trial methodologies aimed at optimizing treatment regimens based on early data.
• The use of Annamycin, a next-generation anthracycline, addresses the limitations of traditional anthracyclines like doxorubicin, which are known for cardiotoxicity.
• Companies like Celgene (now Bristol Myers Squibb) with Revlimid and Novartis with Rydapt have set benchmarks in AML treatment, and Moleculin aims to compete with a novel approach.

Stakeholder Impact

• Positive for patients with R/R AML who may benefit from a new treatment option.
• Positive for shareholders as the company progresses its clinical development program.
• Positive for investigators and clinical sites involved in the MIRACLE trial.

Next Steps

• Continue site initiation and enrollment efforts for the MIRACLE trial.
• Secure additional regulatory approvals in other countries.
• Achieve first subject treatment in the first quarter of 2025.
• Reach the first unblinding (45 subjects) in the second half of 2025.
• Reach the second unblinding (at 75 to 90 subjects) in the first half of 2026.

Key Dates

Keywords

Annamycin, AML, MIRACLE Trial, Moleculin Biotech, Cytarabine, R/R AML, Clinical Trial, Regulatory Approval